Journal: BMC Immunology
Article Title: Enterococcus faecalis KU-EF-004 enhances efficacy of anti-CTLA-4 immunotherapy for colorectal cancer via dendritic cell activation and gut microbiota modulation
doi: 10.1186/s12865-026-00827-7
Figure Lengend Snippet: Antitumor effect of E. faecalis ATCC and KU-EF-004 oral administrations and ICI against MC38. Mean tumor growth curves Mice were divided into four groups: PBS, PBS + anti-PD-1 + anti-CTLA-4 (ICI), E. faecalis ATCC + ICI, and KU-EF-004 + ICI ( n = 4 for all groups). The KU-EF-004 + ICI group showed suppressed tumor growth compared to the other groups, including the E. faecalis ATCC group, at day 19, although the difference was not statistically significant. Each data point presents the average tumor volumes of each group (mean, ± SEM). Data are representative of one independent experiment
Article Snippet: KU-EF-004 strains, along with E. faecalis ATCC 700,802 strain, were each cultured and collected by centrifugation.
Techniques: